Italian pharmaceutical R&D excellence at the 33rd Congress of the European Association of Urology

No new drug treatments for primary or recurrent papillary bladder cancer in 15 years

Oncofid®P-B is a Paclitaxel-Hyaluronan Bioconjugate developed and patented by Fidia farmaceutici, a leading Italian pharmaceutical multinational company

Copenhagen, March 18, 2018 – Fidia farmaceutici today announced the positive results from a phase II…

Sleep problems may affect performance at work and quality of life, as well as have an impact on some chronic diseases

The “Sleep & Health” Project 2018 focuses on the cardiometabolic comorbidities of insomnia, and si dedicated to GPs and specialists (cardiologists, endocrinologists, geriatric physicians, diabetologists, neurologists, internists, and psychiatrists).

Insomnia and disruption of the sleep-wake cycle start a cascade of events that involve different…

Poster Title: Articular Cartilage Lubrication by HYADD®4 Reduces Tissue Strains, Chondrocyte Death, and Apoptosis

“This current study is consistent with the idea that hyaluronic acid therapies for arthritis may act in part through a mechanical pathway that preserves viability of chondrocytes at the cartilage surface,” states Dr. Bonassar.*

Florham Park, NJ, March 9, 2018 – Fidia Farmaceutici, a world leader in the research, development…


Find out more about Fidia’s product portfolio:

Go to the website

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint healthcare
- ophthalmology
- wound care
- dermatology
- neurology
- dermo-aesthetics